Background And Purpose: The end expiration breath hold (EEBH) technique has the potential to reduce tumour motion during radiotherapy treatment of lower oesophageal cancer, and therefore, motion artefacts, target volumes and dose to surrounding organs at risk (OAR). EEBH is an emerging technique and clinical data on its use in oesophageal cancer is scarce.
Methods And Materials: A comparison of 20 lower oesophageal cancer patients was performed for radiotherapy treatment plans in both EEBH and free breathing (FB). EEBH and FB plans were evaluated and compared in terms of motion artefacts, target volumes and dose-volume metrics.
Results: EEBH was effective in reducing the observed motion artefacts seen in planning CTs compared to FB. EEBH also significantly reduced the average PTV size between EEBH and FB (ΔV = -48 ± 55 cm; p < 0.001). OAR-PTV overlap volumes were also effectively reduced in EEBH compared to FB, including for lung-PTV overlaps (ΔV = -13 ± 13 cm; p < 0.001) and for heart-PTV overlaps (ΔV = -8 ± 14 cm; p = 0.02). Mean heart doses were lower on average by -1.2 ± 2.0 Gy with EEBH (p = 0.02), and mean lung doses by -1.0 ± 1.0 Gy (p < 0.001). Mean liver doses were on average reduced with EEBH by -0.6 ± 1.5 Gy, whereas spinal D3 increased in EEBH compared to FB by 1.8 ± 6.3 Gy, but neither were statistically significant.
Conclusion: Use of EEBH for oesophageal cancer radiotherapy reduced motion artefacts and increased confidence in contouring volumes. Additionally, planning target volumes and doses to key OARs were reduced with EEBH compared to FB plans.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11871499 | PMC |
| http://dx.doi.org/10.1016/j.phro.2025.100726 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Potential New Tumors Associated with Hereditary Breast and Ovarian Cancer (HBOC).
Keio J Med
March 2025
Center for Hereditary Breast and Ovarian Cancer Syndrome, Keio University Hospital, Tokyo, Japan.
Hereditary breast and ovarian cancer syndrome (HBOC) is traditionally associated with mutations in the BRCA1 and BRCA2 genes, predominantly impacting breast, ovarian, pancreatic, and prostate cancers. However, recent research suggests that these mutations may also predispose carriers to a broader spectrum of malignancies, including biliary tract, cervical, colorectal, endometrial, esophageal, and gastric cancers. This review presents findings from extensive datasets, including a significant study from a nationwide Japanese biobank that examined cancer risks in 63,828 patients and 37,086 controls.
View Article and Find Full Text PDFNon-coding RNAs in thoracic disease: Barrett's esophagus and esophageal adenocarcinoma.
Clin Chim Acta
March 2025
Department of Medicine, Hunan University of Arts and Science, Changde, Hunan Province 415000, China.
Esophageal adenocarcinoma (EAC) is a highly aggressive malignancy with increasing incidence and poor survival rates, primarily due to late-stage diagnosis. This cancer often develops from Barrett's Esophagus (BE), a precancerous condition linked to chronic gastroesophageal reflux disease (GERD). The transition from BE to EAC is a complex multistep process involving numerous genetic, epigenetic, and molecular changes that lead to the malignant transformation of the esophageal epithelium.
View Article and Find Full Text PDFComparative analysis of protein expression between oesophageal adenocarcinoma and normal adjacent tissue.
PLoS One
March 2025
Centre for Proteomic Research, Biological Sciences and Institute for Life Sciences, Building 85, University of Southampton, Southampton, United Kingdom.
Oesophageal adenocarcinoma (OAC) is the 7th most common cancer in the United Kingdom (UK) and remains a significant health challenge. This study presents a proteomic analysis of seven OAC donors complementing our previous neoantigen identification study of their human leukocyte antigen (HLA) immunopeptidomes. Our small UK cohort were selected from donors undergoing treatment for OAC.
View Article and Find Full Text PDFBiomarkers in gastroesophageal cancer 2025: an updated consensus statement by the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP).
Clin Transl Oncol
March 2025
Pathology Department, Hospital del Mar, Pompeu Fabra University, Hospital del Mar Research Institute, Barcelona, Spain.
Gastroesophageal carcinomas, including gastroesophageal adenocarcinoma (GEA) and esophageal squamous cell carcinoma (ESCC), pose a global health challenge due to their heterogeneity. The approach to diagnosis and treatment should first differentiate between GEA and ESCC. Over the past decade, therapies for metastatic or advanced GEA/ESCC have expanded, with several new therapeutic targets alongside trastuzumab for metastatic HER2-positive GEA.
View Article and Find Full Text PDFLncRNA-DANCR Promotes ESCC Progression and Function as ceRNA to Regulate DDIT3 Expression by Sponging microRNA-3193.
Cancer Sci
March 2025
Translational Medicine Research Center, Department of Pathology & Shanxi Key Laboratory of Carcinogenesis and Translational Research of Esophageal Cancer, Shanxi Medical University, Taiyuan, Shanxi, China.
Long non-coding RNAs (lncRNAs) have emerged as crucial regulators of cancer development and progression. Among them, Differentiation Antagonizing Non-Protein Coding RNA (DANCR) has been implicated in various malignancies, including esophageal squamous cell carcinoma (ESCC). This study explores the clinical characteristics, prognostic implications, functional roles, and molecular mechanisms of DANCR in ESCC.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!